Recce Pharmaceuticals (ASX:RCE) Presentation, FNN Investor Event, November 2018, Melbourne

Company Presentations

Recce Pharmaceuticals Limited (ASX:RCE) Executive Director, James Graham provides an update on the company's RECCE 327 product for use in targeting antibiotic resistant bacteria and its clinical pathway at FNN's Investor Event.

Key points:


  • A drug discovery and development business
  • Commercialising a new class of synthetic antibiotics for resistant superbugs
  • Qualified Infectious Disease Product designation RECCE 327
  • Sepsis kills more people in the U.S. than prostate, breast and lung cancer
  • Sepsis is the number 1 most expensive condition
  • Currently no drug therapies specifically for the treatment of sepsis

For more, watch Executive Director, James Graham present.